Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,515.41
(
-0.05%
)
US TECH 100
29,094.00
(
-0.40%
)
Dow Jones
50,760.52
(
0.59%
)
Brent Oil
94.10
(
-2.98%
)
Bitcoin
75,172.36
(
-0.89%
)
News Focus
News Focus
Post# of 883
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123024
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 86

Sunday, 06/26/2011 7:38:02 PM

Sunday, June 26, 2011 7:38:02 PM

Post# of 883
ABT ‘ReadMeFirst’ updated:

ABT licenses anti-CD4 mAb from Biotest AG;
Bardoxolone advances to phase-3;
ABT submits PMA for Crizotinib diagnostic;
ABT is a beneficiary of The Global Diabetic Tailwind;
NIH terminates AIM-HIGH study;
“Once is happenstance, twice is coincidence, three times…”

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64633397

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ABT News
More ABT News